Trials / Recruiting
RecruitingNCT03862677
Determining Prognostic Immune Markers in Patients With Ovarian Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Leiden University Medical Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).
Detailed description
Tumor material, ascites (if possible) and blood samples for immune monitoring will be collected from patients with primary and recurrent EOC undergoing surgery, chemotherapy and/or immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | Observational study, no intervention |
Timeline
- Start date
- 2020-08-15
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
- First posted
- 2019-03-05
- Last updated
- 2026-02-13
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03862677. Inclusion in this directory is not an endorsement.